S. Negrier, B. Escudier, and C. Lasset, Recombinant Human Interleukin-2, Recombinant Human Interferon Alfa-2a, or Both in Metastatic Renal-Cell Carcinoma, New England Journal of Medicine, vol.338, issue.18
DOI : 10.1056/NEJM199804303381805

G. Francais-d-'immunotherapie-motzer, R. Hutson, T. Tomczak, and P. , Sunitinib versus Interferon Alfa in Metastatic Renal?Cell Carcinoma, N Engl J Med N Engl J Med, vol.338356, issue.2, pp.115-139, 1998.

B. Escudier, T. Eisen, and W. Stadler, Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.2, pp.125-159, 2007.
DOI : 10.1056/NEJMoa060655

G. Hudes, M. Carducci, and P. Tomczak, Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma, New England Journal of Medicine, vol.356, issue.22, pp.2271-81, 2007.
DOI : 10.1056/NEJMoa066838

D. Heng, K. Chi, and N. Murray, A population-based study evaluating the impact of sunitinib on overall survival in the treatment of patients with metastatic renal cell cancer, Cancer, vol.23, issue.4, pp.776-83, 2009.
DOI : 10.1002/cncr.24051

U. Harmenberg, T. Wahlgren, and J. Kowalski, Treatment and overall survival (OS) in metastatic renal cell carcinoma (mRCC): A Swedish population-based study (2000???2008)., Journal of Clinical Oncology, vol.30, issue.5_suppl, p.389, 2012.
DOI : 10.1200/jco.2012.30.5_suppl.389

M. Crepel, B. Escudier, and J. Machiels, Comparison of two major prognostic models for patients with metastatic renal cell carcinoma treated in the contemporary era of targeted therapies., Journal of Clinical Oncology, vol.29, issue.15_suppl, p.4660, 2011.
DOI : 10.1200/jco.2011.29.15_suppl.4660

D. Heng, W. Xie, and M. Regan, Prognostic Factors for Overall Survival in Patients With Metastatic Renal Cell Carcinoma Treated With Vascular Endothelial Growth Factor?Targeted Agents: Results From a Large, Multicenter Study An indirect comparison of the toxicity of sunitinib and pazopanib in metastatic clear cell renal cancer, J Clin Oncol Eur J Cancer, vol.2748, pp.3171-3177, 2009.

D. Fiore, F. Rigal, O. Menager, and C. , Severe clinical toxicities are correlated with survival in patients with advanced renal cell carcinoma treated with sunitinib and sorafenib, British Journal of Cancer, vol.17, issue.12, pp.1811-1814, 2011.
DOI : 10.1038/sj.bjc.6604456

A. Molina, D. Feldman, and M. Voss, Phase 1 trial of everolimus plus sunitinib in patients with metastatic renal cell carcinoma, Cancer, vol.28, issue.18 suppl, pp.1868-76, 2012.
DOI : 10.1002/cncr.26429

S. Negrier, G. Gravis, and D. Perol, Temsirolimus and bevacizumab, or sunitinib, or interferon alfa and bevacizumab for patients with advanced renal cell carcinoma (TORAVA): a randomised phase 2 trial, The Lancet Oncology, vol.12, issue.7, pp.673-80, 2011.
DOI : 10.1016/S1470-2045(11)70124-3

B. Escudier, T. Eisen, and C. Porta, Renal cell carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow?up, Ann Oncol, vol.23, 2012.

C. Sternberg, I. Davis, and J. Mardiak, Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial, Journal of Clinical Oncology, vol.28, issue.6, pp.1061-85, 2010.
DOI : 10.1200/JCO.2009.23.9764

B. Rini, B. Escudier, and P. Tomczak, Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial, The Lancet, vol.378, issue.9807, pp.1931-1940, 2011.
DOI : 10.1016/S0140-6736(11)61613-9

D. Nosov, B. Esteves, and O. Lipatov, Antitumor Activity and Safety of Tivozanib (AV-951) in a Phase II Randomized Discontinuation Trial in Patients With Renal Cell Carcinoma, Journal of Clinical Oncology, vol.30, issue.14, pp.1678-85, 2012.
DOI : 10.1200/JCO.2011.35.3524

J. Brahmer, S. Tykodi, and L. Chow, Safety and Activity of Anti???PD-L1 Antibody in Patients with Advanced Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2455-65, 2012.
DOI : 10.1056/NEJMoa1200694

S. Topalian, F. Hodi, and J. Brahmer, Safety, Activity, and Immune Correlates of Anti???PD-1 Antibody in Cancer, New England Journal of Medicine, vol.366, issue.26, pp.2443-54, 2012.
DOI : 10.1056/NEJMoa1200690